SE0102327D0 - A novel engineered superantigen for human therapy - Google Patents

A novel engineered superantigen for human therapy

Info

Publication number
SE0102327D0
SE0102327D0 SE0102327A SE0102327A SE0102327D0 SE 0102327 D0 SE0102327 D0 SE 0102327D0 SE 0102327 A SE0102327 A SE 0102327A SE 0102327 A SE0102327 A SE 0102327A SE 0102327 D0 SE0102327 D0 SE 0102327D0
Authority
SE
Sweden
Prior art keywords
superantigen
human therapy
novel engineered
engineered superantigen
novel
Prior art date
Application number
SE0102327A
Other languages
English (en)
Swedish (sv)
Inventor
Goeran Forsberg
Eva Erlandsson
Per Antonsson
Bjoern Walse
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to SE0102327A priority Critical patent/SE0102327D0/xx
Publication of SE0102327D0 publication Critical patent/SE0102327D0/xx
Priority to US09/900,766 priority patent/US7125554B2/en
Priority to IL15956202A priority patent/IL159562A0/xx
Priority to YU101503A priority patent/RS52581B/en
Priority to CA2451847A priority patent/CA2451847C/en
Priority to DK02746240.7T priority patent/DK1406657T3/en
Priority to BR0210568-3 priority patent/BRPI0210568B8/pt
Priority to MXPA03011761A priority patent/MXPA03011761A/es
Priority to EEP200400037A priority patent/EE05475B1/xx
Priority to UA2004010601A priority patent/UA85993C2/ru
Priority to HU0400313A priority patent/HUP0400313A3/hu
Priority to PCT/SE2002/001188 priority patent/WO2003002143A1/en
Priority to PL368048A priority patent/PL216516B1/pl
Priority to SK1611-2003A priority patent/SK16112003A3/sk
Priority to CZ2003-3559A priority patent/CZ307180B6/cs
Priority to ES02746240.7T priority patent/ES2564041T3/es
Priority to EP02746240.7A priority patent/EP1406657B1/en
Priority to KR1020037016268A priority patent/KR100961054B1/ko
Priority to NZ529827A priority patent/NZ529827A/en
Priority to RU2004102199/13A priority patent/RU2307837C2/ru
Priority to CN028131045A priority patent/CN1522156B/zh
Priority to JP2003508382A priority patent/JP4523773B2/ja
Priority to ZA2003/09150A priority patent/ZA200309150B/en
Priority to HRP20031054AA priority patent/HRP20031054B1/hr
Priority to IS7083A priority patent/IS2986B/is
Priority to NO20035773A priority patent/NO333676B1/no
Priority to BG108499A priority patent/BG66321B1/bg
Priority to IL159562A priority patent/IL159562A/en
Priority to HK04110098.6A priority patent/HK1067980A1/xx
Priority to US11/526,437 priority patent/US7615225B2/en
Priority to US12/568,579 priority patent/US20100111978A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/06—Message adaptation to terminal or network requirements
    • H04L51/063—Content adaptation, e.g. replacement of unsuitable content
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/58—Message adaptation for wireless communication

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SE0102327A 2001-06-28 2001-06-28 A novel engineered superantigen for human therapy SE0102327D0 (sv)

Priority Applications (31)

Application Number Priority Date Filing Date Title
SE0102327A SE0102327D0 (sv) 2001-06-28 2001-06-28 A novel engineered superantigen for human therapy
US09/900,766 US7125554B2 (en) 2001-06-28 2001-07-06 Engineered superantigen for human therapy
JP2003508382A JP4523773B2 (ja) 2001-06-28 2002-06-19 ヒト治療用新規組換えスーパー抗原
CZ2003-3559A CZ307180B6 (cs) 2001-06-28 2002-06-19 Konjugát obsahující superantigen a protilátkovou skupinu, a farmaceutický prostředek s obsahem konjugátu
KR1020037016268A KR100961054B1 (ko) 2001-06-28 2002-06-19 암을 치료하기 위해 조작한 신규한 초항원을 포함하는 접합체, 이를 포함하는 조성물 및 이를 사용하는 방법
CA2451847A CA2451847C (en) 2001-06-28 2002-06-19 A novel engineered superantigen for human therapy
DK02746240.7T DK1406657T3 (en) 2001-06-28 2002-06-19 NEW TECHNICAL MADE superantigen TO TREAT PEOPLE
BR0210568-3 BRPI0210568B8 (pt) 2001-06-28 2002-06-19 conjugado, uso de um conjugado, e, composição farmacêutica
MXPA03011761A MXPA03011761A (es) 2001-06-28 2002-06-19 Un nuevo superantigeno disenado para terapia humana.
EEP200400037A EE05475B1 (et) 2001-06-28 2002-06-19 Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon
UA2004010601A UA85993C2 (ru) 2001-06-28 2002-06-19 Конъюгат, который содержит бактериальный суперантиген и антительную составную, фармацевтическая композиция, которая его содержит, и способ лечения рака у млекопитающего
HU0400313A HUP0400313A3 (en) 2001-06-28 2002-06-19 A novel engineered superantigen for human therapy
PCT/SE2002/001188 WO2003002143A1 (en) 2001-06-28 2002-06-19 A novel engineered superantigen for human therapy
PL368048A PL216516B1 (pl) 2001-06-28 2002-06-19 Koniugat obejmujący superantygen bakteryjny i część stanowiącą przeciwciało, zastosowanie tego koniugatu i kompozycja farmaceutyczna
SK1611-2003A SK16112003A3 (en) 2001-06-28 2002-06-19 A novel engineered superantigen for human therapy
IL15956202A IL159562A0 (en) 2001-06-28 2002-06-19 A novel engineered superantigen for human therapy
ES02746240.7T ES2564041T3 (es) 2001-06-28 2002-06-19 Un nuevo superantígeno modificado genéticamente para terapia humana
EP02746240.7A EP1406657B1 (en) 2001-06-28 2002-06-19 A novel engineered superantigen for human therapy
YU101503A RS52581B (en) 2001-06-28 2002-06-19 NEW CONSTRUCTED SUPERANTIGEN FOR HUMAN THERAPY
NZ529827A NZ529827A (en) 2001-06-28 2002-06-19 A novel engineered superantigen for human therapy
RU2004102199/13A RU2307837C2 (ru) 2001-06-28 2002-06-19 Новый биотехнологически созданный суперантиген для лечения человека
CN028131045A CN1522156B (zh) 2001-06-28 2002-06-19 用于人类治疗的新型工程超级抗原
ZA2003/09150A ZA200309150B (en) 2001-06-28 2003-11-25 A novel engineered superantigen for human therapy
HRP20031054AA HRP20031054B1 (hr) 2001-06-28 2003-12-17 Novo proizveden superantigen za humanu terapiju
IS7083A IS2986B (is) 2001-06-28 2003-12-18 Nýr tilbúinn fjölræsivaki til að nota við meðferð á manneskjum
NO20035773A NO333676B1 (no) 2001-06-28 2003-12-22 Nytt konstruert superantigen for human terapi
BG108499A BG66321B1 (bg) 2001-06-28 2003-12-22 Генноинженерно получен конюгат за лечение на хора, който съдържа суперантиген
IL159562A IL159562A (en) 2001-06-28 2003-12-24 Conjugate comprising a modified bacterial superantigen and an antibody moiety and use thereof in the treatment of cancer
HK04110098.6A HK1067980A1 (en) 2001-06-28 2004-12-21 A novel engineered superantigen for human therapy
US11/526,437 US7615225B2 (en) 2001-06-28 2006-11-21 Methods for treating a subject having cancer by the administration of a conjugate between a variant staphylococcal entertoxin E superantigen and an antibody that binds to the 5T4 antigen
US12/568,579 US20100111978A1 (en) 2001-06-28 2009-09-28 Conjugates between a variant staphylococcal enterotoxin e superantigen and a targeting antibody that binds to a cancer-associated cell surface structure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102327A SE0102327D0 (sv) 2001-06-28 2001-06-28 A novel engineered superantigen for human therapy

Publications (1)

Publication Number Publication Date
SE0102327D0 true SE0102327D0 (sv) 2001-06-28

Family

ID=20284677

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0102327A SE0102327D0 (sv) 2001-06-28 2001-06-28 A novel engineered superantigen for human therapy

Country Status (28)

Country Link
US (3) US7125554B2 (xx)
EP (1) EP1406657B1 (xx)
JP (1) JP4523773B2 (xx)
KR (1) KR100961054B1 (xx)
CN (1) CN1522156B (xx)
BG (1) BG66321B1 (xx)
BR (1) BRPI0210568B8 (xx)
CA (1) CA2451847C (xx)
CZ (1) CZ307180B6 (xx)
DK (1) DK1406657T3 (xx)
EE (1) EE05475B1 (xx)
ES (1) ES2564041T3 (xx)
HK (1) HK1067980A1 (xx)
HR (1) HRP20031054B1 (xx)
HU (1) HUP0400313A3 (xx)
IL (2) IL159562A0 (xx)
IS (1) IS2986B (xx)
MX (1) MXPA03011761A (xx)
NO (1) NO333676B1 (xx)
NZ (1) NZ529827A (xx)
PL (1) PL216516B1 (xx)
RS (1) RS52581B (xx)
RU (1) RU2307837C2 (xx)
SE (1) SE0102327D0 (xx)
SK (1) SK16112003A3 (xx)
UA (1) UA85993C2 (xx)
WO (1) WO2003002143A1 (xx)
ZA (1) ZA200309150B (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
ES2284209T3 (es) * 1997-07-21 2007-11-01 Active Biotech Ab Citolisis de celulas diana por conjugados de superantigenos que inducen la activacion de celulas t.
US7491402B2 (en) * 1998-12-24 2009-02-17 Auckland Uniservices Limited Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
MXPA05001933A (es) * 2002-08-19 2005-04-28 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
DE602004026039D1 (de) * 2003-03-28 2010-04-29 Kowa Co Seb-modifikation und diese enthaltendes vorbeugendes mittel/heilmittel gegen krankheiten mit einer immunanomalität
SE0402025D0 (sv) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
US20080274133A1 (en) * 2004-11-18 2008-11-06 Avidex Ltd. Soluble Bifunctional Proteins
GB0427585D0 (en) * 2004-12-16 2005-01-19 Avidex Ltd Assay
CA2676143A1 (en) * 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013041687A1 (en) 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
CN102516392B (zh) * 2011-11-25 2014-05-28 孙嘉琳 一种癌靶向超抗原融合蛋白及制备方法及用途
MX2014007233A (es) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
CN103965302B (zh) * 2013-01-29 2019-05-28 军事科学院军事医学研究院微生物流行病研究所 一种重组超抗原seb突变体，其制备方法及应用
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
AU2017206656B2 (en) 2016-01-10 2024-02-01 Neotx Therapeutics Ltd. Immunopotentiator enhanced superantigen mediated cancer immunotherapy
JP7303791B2 (ja) * 2017-07-27 2023-07-05 アブヴァク インコーポレイテッド スーパー抗原トキソイドに由来する融合ペプチドを含む免疫原性組成物
MX2021013908A (es) 2019-05-15 2022-03-11 Neotx Therapeutics Ltd Tratamiento para el cáncer.
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物
MX2023003581A (es) * 2020-09-28 2023-06-21 Janssen Pharmaceuticals Inc Polipeptidos variantes de luka y lukb de staphylococcus aureus y composiciones de vacuna.
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US5221605A (en) 1984-10-31 1993-06-22 Igen, Inc. Luminescent metal chelate labels and means for detection
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5284760A (en) 1989-04-03 1994-02-08 Feinstone Stephen M Techniques for producing site-directed mutagenesis of cloned DNA
US6042837A (en) 1989-09-20 2000-03-28 Kalland; Terje Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC)
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6126945A (en) 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
EP0511306B1 (en) * 1990-01-17 2002-07-17 TERMAN, David S. Tumor killing effects of enterotoxins and related compounds
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
EP0527809B1 (en) 1990-04-05 1995-08-16 CREA, Roberto Walk-through mutagenesis
US5858363A (en) 1990-07-20 1999-01-12 Pharmacia & Upjohn Ab Target specific antibody-superantigen conjugates and their preparation
US6197299B1 (en) 1990-07-20 2001-03-06 Pharmacia & Upjohn Ab Antibody conjugates
WO1993024136A1 (en) 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
JPH06505486A (ja) 1991-02-07 1994-06-23 モレキュメティクス，リミティド βターンおよびβバルジのコンフォメーション的に制限された模倣物およびそれらを含有するペプチド
ATE239089T1 (de) 1991-12-24 2003-05-15 Harvard College Gezielte punkt-mutagenese von dna
US5389514A (en) 1992-08-28 1995-02-14 Fox Chase Cancer Center Method for specifically altering the nucleotide sequence of RNA
US5545716A (en) 1992-09-08 1996-08-13 University Of Florida Superantigen agonist and antagonist peptides
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5519114A (en) 1993-10-29 1996-05-21 University Of Florida Research Foundation, Inc. Retroviral superantigens, superantigen peptides, and methods of use
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
US5935568A (en) 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
PT832241E (pt) 1995-06-07 2005-08-31 Univ Minnesota Mutantes de toxina a estreptococica e metodos de utilizacao
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5840833A (en) 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
EP0891436B1 (de) 1996-03-27 2001-11-28 Zellweger Luwa Ag Verfahren und vorrichtung zur qualitätsüberwachung von garnen
AU2429397A (en) 1996-03-29 1997-10-22 David S. Terman Polymerized staphylococcal protein a for treatment of diseases
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
DK0946730T3 (da) 1996-12-06 2006-07-10 Univ Minnesota Mutanter af streptokok-toksin C og fremgangsmåder til anvendelse
US6774218B2 (en) 1996-12-06 2004-08-10 Regents Of The University Of Minnesota Mutants of streptococcal toxin C and methods of use
CN1211487C (zh) 1996-12-06 2005-07-20 明尼苏达大学董事会 链球菌毒素a突变体及其使用方法
US6340461B1 (en) 1996-12-17 2002-01-22 David Stephen Terman Superantigen based methods and compositions for treatment of diseases
IL119938A (en) 1996-12-30 2005-08-31 Yissum Res Dev Co Peptides capable of eliciting protective immunity against toxic shock induced by pyrogenic exotoxins or of antagonizing toxin-mediated activation of t cells
US7087235B2 (en) 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
US6713284B2 (en) 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
ES2284209T3 (es) 1997-07-21 2007-11-01 Active Biotech Ab Citolisis de celulas diana por conjugados de superantigenos que inducen la activacion de celulas t.
WO1999036433A2 (en) 1998-01-14 1999-07-22 Morphogenesis, Inc. Materials and methods for treating oncological disease
WO2000002522A2 (en) 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Anthrax vaccine
US20050112141A1 (en) * 2000-08-30 2005-05-26 Terman David S. Compositions and methods for treatment of neoplastic disease
US20020177551A1 (en) 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
SE9903895D0 (sv) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
JP2003515323A (ja) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
US20030157113A1 (en) 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
US20010046501A1 (en) 2000-03-14 2001-11-29 Johnson Howard M. Superantigen enhancement of specific immune responses
JP4283430B2 (ja) 2000-09-26 2009-06-24 株式会社カネカ エンテロトキシンの吸着材、吸着除去方法および吸着器
DE60139954D1 (de) 2000-12-04 2009-10-29 Auckland Uniservices Ltd Immunmodulatorische konstruktionen und ihre verwendung
CN1369550A (zh) 2001-02-16 2002-09-18 沈阳协合集团有限公司 一种金黄色葡萄球菌的培养物及其制备方法
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
AU2003266289A1 (en) * 2002-08-21 2004-03-11 Merck Patent Gmbh T-cell epitopes in staphylococcal enterotoxin b
WO2006004620A2 (en) * 2004-06-29 2006-01-12 Terman David S Enterotoxin gene cluster (egc) superantigens to treat malignant disease
US20060005711A1 (en) 2004-07-07 2006-01-12 Andrew Olefson Replaceable filter for a vehicle air conditioning system adapted to scent air
SE0402025D0 (sv) 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
US20070280905A1 (en) * 2006-06-01 2007-12-06 Shulin Li Prognosis and Systemic Therapy for Treating Malignancy

Also Published As

Publication number Publication date
HRP20031054A2 (en) 2004-04-30
DK1406657T3 (en) 2016-03-07
EP1406657B1 (en) 2015-12-30
EE05475B1 (et) 2011-10-17
HUP0400313A2 (hu) 2004-09-28
JP2005503362A (ja) 2005-02-03
US20070082001A1 (en) 2007-04-12
RU2307837C2 (ru) 2007-10-10
US20030039655A1 (en) 2003-02-27
IS2986B (is) 2017-09-15
PL216516B1 (pl) 2014-04-30
US7125554B2 (en) 2006-10-24
IL159562A0 (en) 2004-06-01
ZA200309150B (en) 2005-01-26
EP1406657A1 (en) 2004-04-14
EE200400037A (et) 2004-04-15
NZ529827A (en) 2005-06-24
CZ20033559A3 (en) 2004-06-16
HRP20031054B1 (hr) 2016-12-30
YU101503A (xx) 2006-05-25
US7615225B2 (en) 2009-11-10
HK1067980A1 (en) 2005-04-22
RS52581B (en) 2013-04-30
BRPI0210568B1 (pt) 2020-10-13
CN1522156A (zh) 2004-08-18
IL159562A (en) 2010-12-30
RU2004102199A (ru) 2005-05-20
IS7083A (is) 2003-12-18
NO333676B1 (no) 2013-08-05
CZ307180B6 (cs) 2018-02-28
PL368048A1 (en) 2005-03-21
KR20040015264A (ko) 2004-02-18
JP4523773B2 (ja) 2010-08-11
BG108499A (en) 2005-03-31
BG66321B1 (bg) 2013-05-31
BRPI0210568B8 (pt) 2021-05-25
UA85993C2 (ru) 2009-03-25
US20100111978A1 (en) 2010-05-06
BR0210568A (pt) 2004-08-03
CA2451847C (en) 2012-10-16
WO2003002143A1 (en) 2003-01-09
NO20035773L (no) 2004-02-27
CN1522156B (zh) 2012-10-10
CA2451847A1 (en) 2003-01-09
HUP0400313A3 (en) 2006-02-28
SK16112003A3 (en) 2004-11-03
KR100961054B1 (ko) 2010-06-01
MXPA03011761A (es) 2004-04-02
ES2564041T3 (es) 2016-03-17

Similar Documents

Publication Publication Date Title
SE0102327D0 (sv) A novel engineered superantigen for human therapy
EP2371389A3 (en) FcgammaRIIB-specific antibodies and methods of use thereof
TR200901979T2 (tr) Antikolinerjik etkili bileşik ve ?-mimetikler bazında yeni ilaç bileşimleri.
AU2002215935A1 (en) Novel use of short-chained carboxylic acids
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
NO20041917L (no) Spesifikke midler som binder humant angiopoietin-2
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
HRP20080564T3 (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
MXPA05009682A (es) Metodos de radiofluorinacion de vectores biologicamente activos.
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
EA200701293A1 (ru) Терапевтическая композиция фактора роста кератиноцитов
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
AU2002221908A1 (en) Novel use of protein hydrolysates
NO20031860L (no) Kahalalid F
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
MY130373A (en) Linear basic compounds having nk-2 antagonist activity and formulations thereof
BR0010699A (pt) Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários
ATE392644T1 (de) Alpha-(1' -hydroxyalkyl)acrylate enthaltende beschichtungsmassen
MXPA03004111A (es) Composiciones de n-(1 -metiletilaminocarbonil)-4 -(3-metilfenilamino) -3-piridil-sulfonamida y oligosacaridos ciclicos con una mayor liberacion.
DE59809344D1 (de) Disubstituierte biphenyloxazoline
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
EP1370697A4 (en) PEROXYREDOXIN-BASED MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV-1 INFECTIONS AND METHODS OF USE
CY1105981T1 (el) Ενωσεις 5-πυριδυλ-1,3-αζολιου, μεθοδοι παρασκευης αυτων και χρηση αυτων
RS51793B (en) POLIMERNI conjugated HMGB1 HMGB1 VARIJANTI I BOX A BOX A